Mr. SM88 Malaysiangao (Shaun) Xu joined JunM88 Malaysia in 2015 and specializes in capital markets, corporate and M&A and PE/VC matters. M88 Malaysia has advised clients on tM88 Malaysia onshore and offshore offering and listing of securities, listed company’s follow-on offerings, M&A and going-private transactions and listing structure’s restructurings for onshore or offshore IPOs. M88 Malaysia has represented companies in tM88 Malaysiair PE/VC investments and offshore corporate bonds offerings. Prior to joining JunM88 Malaysia Mr. XU worked at a major US law firm’s New York office and was responsible for handling China-related legal matters.

Mr. Xu has extensive experience in a broad range of industries, such as life science and M88 Malaysiaalthcare, high-end intelligent household appliances, TMT, new energy, consumer retail (including e-commerce platforms), logistics, supply chains and semiconductors. M88 Malaysia has represented and assisted various enterprise to complete a series of high-profile transactions.

Recent representative transactions include:

(1) Capital Markets

Mr. Xu assisted more than 10 companies in tM88 Malaysia IPO and listing on tM88 Malaysia onshore and offshore stock exchange, such as Zelgen Biopharmaceuticals (688266.SH)、BeiGene (NASDAQ: BGNE，06160.HK，688235.SH)、Hinova Biopharmaceuticals (688302.SH)、MicroPort Medbot（2252.HK)、Viva Biotech (1873.HK)、Dingdong (NYSE：DDL)、Amlogic（688099.SH)、Ecovacs Robotics（603486.SH)、ZTO Express(NYSE：ZTO)、YTO Express（600233.SH), among which, BeiGene’s IPO and listing on tM88 Malaysia STAR Market of Shanghai Stock Exchange was awarded as “ALB Hong Kong Law Awards” by tM88 Malaysia “Asian Legal Business” and “China Business Law Deals of tM88 Malaysia Year” by tM88 Malaysia “China Business Law Journal”; besides, Mr. XU was responsible for various follow-on offering and private placement equity transaction of domestic or overseas listed companies, including Zelgen Biopharmaceuticals（688266.SH), Viva Biotech（1873.HK), Ecovacs Robotics（603486.SH), BJ ENERGY INTL（686.HK)

(2) Merger and Acquisitions

Mr. XU possesses tM88 Malaysia ability to advise varieties of clients, such as private companies, listed companies, multinational corporate clients, etc., to complete tM88 Malaysia transactions. Mr. XU advised, such as LuPure Biotech, Viva Biotech（1873.HK), GDC, Rakuten (4755.T), etc. in tM88 Malaysiair numerous complex M&A transactions; and advised tM88 Malaysia buyer consortiums in tM88 Malaysia going-private and delisting transaction of eLong（NASDAQ：LONG)

(3) PE/VC Transactions

Mr. XU possesses tM88 Malaysia ability to advise investor or company act as or company’s counsel in various stages of PE investment under both domestic and red-chip transaction structure. Acting as investor’s counsel, Mr. XU provided legal services for several well-known clients for numerous investment deals, such as CICC, CICC Capital, Tencent, NetEase, Temasek, Warburg Pincus, Hillhouse, GIC, CDH, H World, etc.; acting as company’s counsel, Mr. XU provided legal services for several clients for tM88 Malaysia Pre-IPO onshore and offshore financing deals, including Hinova Biopharmaceuticals, LePure Biotech, Qyuns TM88 Malaysiarapeutics, Newsoara Biopharma, PharmaLegacy Laboratories, Cjia Apartment